Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Pazopanib

Abstract

 Pazopanib

In October 2009, pazopanib (Votrient; GlaxoSmithKline) — a multikinase inhibitor with targets that include vascular endothelial growth factor receptors — was approved by the US FDA for the treatment of advanced renal cell carcinoma.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Targeting growth factor signalling in renal cell carcinoma.

References

  1. 1

    Garcia, J. A. & Rini, B. I. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J. Clin. 57, 112–125 (2007).

    Article  PubMed  Google Scholar 

  2. 2

    Atkins, M. A. et al. Everolimus. Nature Rev. Drug Discov. 8, 535–536 (2009).

    CAS  Article  Google Scholar 

  3. 3

    Heng, D. Y. & Bukowski, R. M. Anti-angiogenic targets in the treatment of advanced renal cell carcinoma. Curr. Cancer Drug Targets 8, 676–682 (2008).

    CAS  Article  PubMed  Google Scholar 

  4. 4

    Harris, P. A. et al. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J. Med. Chem. 51, 4632–4640 (2008).

    CAS  Article  PubMed  Google Scholar 

  5. 5

    Kumar, R. et al. Pharmacokinetic–pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol. Cancer Ther. 6, 2012–2021 (2007).

    CAS  Article  PubMed  Google Scholar 

  6. 6

    Food and Drug Administration. FDA labelling information. FDA website [online], (2009).

  7. 7

    Sternberg, C. N. et al. A randomized, double-blind phase lll study of pazopanib in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J. Clin. Oncol. 27, 15s A5021 (2009).

    Article  Google Scholar 

  8. 8

    Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).

    CAS  Article  Google Scholar 

  9. 9

    Motzer, R. J. et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295, 2516–2524, (2006).

    CAS  Article  Google Scholar 

  10. 10

    Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 372, 449–456 (2008).

    CAS  Article  Google Scholar 

  11. 11

    IMS MIDAS (IMS Health, 2009).

  12. 12

    SG Cowen Research Team. SG Cowen Therapeutic Categories Outlook (Sep 2009).

  13. 13

    Hauber, A., Vosser, R. & Evans, D. JP Morgan Equity Research Report (11 Sep 2009).

Download references

Author information

Affiliations

Authors

Ethics declarations

Competing interests

R.M.B. has received honoraria and acted as a consultant for Pfizer, Novartis and Genentech, and has acted as a consultant for GSK and Bayer.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bukowski, R., Yasothan, U. & Kirkpatrick, P. Pazopanib. Nat Rev Drug Discov 9, 17–18 (2010). https://doi.org/10.1038/nrd3073

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing